The Latest Cardiac and Vascular News
Use of artificial intelligence technology efficiently identifies eligible patient candidates for pivotal clinical trial; program launched at The Christ Health Network SANTA CLARA, Calif. & ALISO VIEJO, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a medical device company developing a novel transcatheter device-based therapy to address heart failure (HF), and egnite, Inc., a leading digital health company in the field of […]
12 Month Data Presented as Late-Breaking Clinical Science at THT 2023 and Simultaneously Published in the Journal of Cardiac Failure BOSTON–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a completely transcatheter device-based therapy to address heart failure (HF), today announced that patients treated with the investigational AccuCinch® Ventricular Restoration System demonstrated improvement in HF patient outcomes and […]
Senior Financial Leader is Company’s Second C-Level Hire in 2022 SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure (HF), today announced that David J. Tucker has joined the company as chief financial officer. He will direct the company’s financial strategies and operations as it continues to […]
Accomplished MedTech Leader with Proven Track Record of Strategic, Operational and Commercial Execution in High Growth Companies SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure (HF), today announced that Mark Miles has joined the company as Chief Commercial Officer (CCO). He will oversee commercialization strategy for […]
Results Presented at Transcatheter Cardiovascular Therapeutics 2021 ORLANDO, Fla.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced results from an analysis of multiple studies that showed positive outcomes with its investigational AccuCinch® Ventricular Restoration System. The results were presented during a Featured Clinical Research Session at the 33rd Transcatheter Cardiovascular […]
Beverly Huss to join Board of Directors SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced it has closed an $80 million equity financing. Sands Capital, Sio Capital and an undisclosed strategic investor joined all existing investors in this financing. The funds will be used to […]
Pivotal Trial to Evaluate Safety and Efficacy of AccuCinch® Ventricular Restoration System in Heart Failure Patients with Reduced Ejection Fraction SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced enrollment of the first patient in the CORCINCH-HF pivotal trial, which is designed to evaluate the safety and […]
Global Study to Evaluate Percutaneous Device Designed for the Mechanical Support of the Ventricle in Heart Failure Patients SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application for the CorCinch-HF pivotal study, […]
SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced the first patient was enrolled in a U.S. early feasibility study evaluating the AccuCinch® Ventricular Repair System as a treatment for patients with reduced ejection fraction systolic heart failure (HFrEF). The first patient was enrolled at UPMC Pinnacle […]
SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced the company’s key activities at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation in San Diego. Interim data will be presented from the recently expanded U.S. early feasibility study evaluating […]
